Since the middle of 2022, when their GLP-1 agonists became recognized as effective treatments for obesity in addition to diabetes, the stock prices of Novo Nordisk A/S and Eli Lilly and Company have soared. Second-quarter earnings reports from both companies firstly led to some weakness for Novo, but then demonstrated that this is not a zero-sum game.
Stock Watch: Some Turbulence As Novo And Lilly Report Results
Investors Should Value Birds In The Hand Above Fledglings In The Bush
Novo disappointed on high expectations with its second-quarter announcement resulting in stock price weakness. But after Lilly reported without disappointment, something unexpected happened.
More from Stock Watch
• By
The promise of innovative therapies seems to have been constrained not by efficacy or safety concerns, but because the high price of treatments is incongruous with the reimbursement of short-course therapies.
• By
After lowering its full-year earnings guidance just six weeks before the end of 2024, Bayer, by talking up of the prospects for its new drug launches and a major clinical trial result in 2025, might risk damaging its integrity further.
• By
CSL’s US influenza vaccine sales were a window into wider issues for vaccine manufacturers that had already impacted the fourth-quarter results of Merck, Pfizer and GSK. There could also be a correlation between lower vaccine sales and the measles outbreak in Texas.
• By
Two pharmaceutical companies reporting bumper sales in the hot areas of diabetes and obesity may have helped a thaw in sector sentiment.
More from Business
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
The Danish firm is spending nearly $580m to repurchase up to 2.2 million shares
• By
Kyoto-based venture moves HQ to California to expand R&D and business outreach for its regulatory T-cell technology, as it raises around $46m in public and private funding.